Featured Articles

1. The MDR Paradox: What The December 2025 Easing Takes Off Your Desk, And What You Still Have To Collect 10/14/2026

   The EU’s proposed MDR easing cuts a report, not the duty to collect real-world clinical data. Learn what still applies and how to pick the right post-market evidence method.

2. The PMCF Decision Guide 10/14/2026

   Proposed EU reforms may remove standalone PMCF reporting, yet the duty to proactively collect clinical data remains. Method selection, notified body defense, and data-capture cost determine what comes next.

3. Accelerating Enrollment For Direct-To-Patient Observational Studies 10/14/2026

   Removing the handoff between patient self-screening and enrollment changes what a fully virtual observational study can achieve, from conversion at peak intent to completion rates among participants.

4. The 2027 RWE Playbook: Regulation, AI & Data Reshape Evidence 9/17/2026

   New guidance is raising the bar for real-world evidence. Get a practical framework for auditing your data sources and closing traceability gaps before 2027.

5. Running Compliant Studies Without Enterprise EDC Overhead 8/19/2026

   Low-complexity medical device and IVD studies often fall between enterprise EDC systems and spreadsheets. This webinar shows how a compliant, audit-ready alternative works in practice.

6. From Hype To Health: The Three Jobs Sword Made Its Clinical Evidence Do 8/19/2026

   A long-term strategy for turning clinical evidence into clinician trust, standard-of-care status, and payer reimbursement for digital care.

7. What 9 Years Of MDR Experience Is Changing About PMCF Planning 7/28/2026

   Re-evaluate your compliance roadmap by exploring expert perspectives on navigating regulatory shifts, distinguishing core surveillance obligations, and building a defensible, value-driven clinical data strategy.

8. UK Clinical Trial Regulations Reform 7/24/2026

   UK trial regulations have been overhauled. Learn what faster approval pathways, stricter publication rules, and longer retention requirements mean for your operations.

9. ICH E6(R3) Annex 2: Navigating GCP Requirements For Decentralized Trials 7/24/2026

   Implementing decentralized components or real-world data requires proactive alignment with updated GCP standards for data access, remote consent, and multi-stream investigator oversight.

10. Early-Stage Biotech's AI Advantage Is A Window That Closes 5/27/2026

    FDA AI guidance won’t build your strategy for you. Learn how biotech teams can avoid retrofits and design smarter clinical AI from day one.